GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
GRI Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.45+0.07 (+5.07%)
Close on Oct 19, 2026
- Market cap
- $2.62M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
4.3%
0M of 2M shares
Institutional holders
11
6 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Intracoastal Capital, LLC | 677,477 | 9.99% | 13G (passive) | Dec 11, 2025 |
| Mitchell P. Kopin | 1,097,858 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GRI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 28,784 | 1.32% | $50 | New | 0.00% |
| Vanguard Capital Management LLC | 21,368 | 0.98% | $37.82K | New | 0.00% |
| Geode Capital Management, LLC | 13,869 | 0.63% | $24.55K | −4,569 | 0.00% |
| Citadel Advisors LLC | 13,376 | 0.61% | $23.68K | New | 0.00% |
| Morgan Stanley | 8,737 | 0.40% | $15.46K | New | 0.00% |
| UBS Group AG | 4,920 | 0.23% | $8.71K | −3,802 | 0.00% |
| Tower Research Capital LLC (TRC) | 2,434 | 0.11% | $4.31K | +1,374 | 0.00% |
| Barclays PLC | 83 | 0.00% | $147 | New | 0.00% |
| BlackRock, Inc. | 7 | 0.00% | $12 | – | 0.00% |
| Danske Bank A/S | 2 | 0.00% | $4 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | 0.00% | $4 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 11 | 0M | 4.3% | 6 / 1 | 2 / 1 | 0M | 0M |
| Q1 2026 | 6 | 0M | 1.3% | 5 / 0 | 1 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GRI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 21,368 | 0.98% | $37.82K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 13,707 | 0.63% | $28.92K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 872 | 0.04% | $1.84K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1 | -0.00% | -$2 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Walter Marc Hertz | Chief Executive Officer, Director | 385,510 | 17.63% | Sep 22, 2025 |
| Leanne Kelly | Chief Financial Officer | 6,250 | 0.29% | Sep 22, 2025 |
| Vipin Chaturvedi | Chief Scientific Officer | 172,189 | 7.88% | Sep 22, 2025 |
| Roelof Rongen | Director | – | – | Sep 22, 2025 |
| David Charles Baker | Director | 7,843 | 0.36% | Sep 22, 2025 |
| David Leslie Szekeres | Director | – | – | Sep 22, 2025 |
| Camilla V. Simpson | Director | – | – | Sep 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Vipin Chaturvedi Chief Scientific Officer | Apr 21, 2023 | Award | +172,189 | – | – | 172,189 |
| Albert Agro Chief Medical Officer | Apr 21, 2023 | Award | +172,189 | – | – | 172,189 |
| Walter Marc Hertz Chief Executive Officer, Director, 10% owner | Apr 21, 2023 | Award | +385,510 | – | – | 385,510 |
| Marella Thorell Director | Dec 13, 2022 | Other | −28,517 | – | – | 9,506 |
| Marella Thorell Director | Jul 1, 2022 | Award | +38,023 | – | – | 38,023 |
| Leanne Kelly Chief Financial Officer | Jun 4, 2021 | Buy | +1,508 | $4.08 | $6.15K | 6,250 |
| Leanne Kelly Chief Financial Officer | Jun 3, 2021 | Buy | +1,085 | $4.05 | $4.39K | 4,742 |
| Leanne Kelly Chief Financial Officer | Jun 2, 2021 | Buy | +3,657 | $4.00 | $14.63K | 3,657 |
| Joseph E. Payne Director | May 26, 2021 | Buy | +6,800 | $4.50 | $30.60K | 17,500 |
| Joseph E. Payne Director | May 25, 2021 | Buy | +10,700 | $3.85 | $41.20K | 10,700 |
| Richard Ammer Director | Feb 12, 2021 | Other | +47,063 | $6.40 | $301.20K | 47,063 |
| David Charles Baker Chief Executive Officer, Director | Feb 12, 2021 | Other | +7,843 | $6.40 | $50.20K | 7,843 |
| David Charles Baker Chief Executive Officer, Director | Feb 12, 2021 | Buy | +1,000 | $8.00 | $8.00K | 8,843 |
| Pharma GmbH SALMON 10% owner | Feb 12, 2021 | Other | +47,063 | $6.40 | $301.20K | 47,063 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.